LGND Quote, Financials, Valuation and Earnings

Dare Bioscience has a net margin of -93.64% compared to Ligand Pharmaceuticals's net margin of -17219.13%. Ligand Pharmaceuticals's return on equity of -16.38% beat Dare Bioscience's return on equity of --.

Ligand Pharmaceuticals has a consensus price target of $143.88, signalling upside risk potential of 13.36%. On the other hand Dare Bioscience has an analysts' consensus of $13.00 which suggests that it could grow by 320.71%. Given that Dare Bioscience has higher upside potential than Ligand Pharmaceuticals, analysts believe Dare Bioscience is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 0.874, which suggesting that the stock is 12.628% less volatile than S&P 500. In comparison Dare Bioscience has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.754%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dare Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Dare Bioscience pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $45.3M, which are larger than Dare Bioscience quarterly revenues of $25.4K. Ligand Pharmaceuticals's net income of -$42.5M is lower than Dare Bioscience's net income of -$4.4M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Dare Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 13.05x versus 1,007.55x for Dare Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -93.64% compared to Ligand Pharmaceuticals's net margin of -907.48%. Ligand Pharmaceuticals's return on equity of -16.38% beat Moderna's return on equity of -29.23%.

Ligand Pharmaceuticals has a consensus price target of $143.88, signalling upside risk potential of 13.36%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 44.79%. Given that Moderna has higher upside potential than Ligand Pharmaceuticals, analysts believe Moderna is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 0.874, which suggesting that the stock is 12.628% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $45.3M, which are smaller than Moderna quarterly revenues of $107M. Ligand Pharmaceuticals's net income of -$42.5M is higher than Moderna's net income of -$971M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 13.05x versus 4.07x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -93.64% compared to Ligand Pharmaceuticals's net margin of -108.46%. Ligand Pharmaceuticals's return on equity of -16.38% beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

Ligand Pharmaceuticals has a consensus price target of $143.88, signalling upside risk potential of 13.36%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $87.21 which suggests that it could grow by 198.36%. Given that Ultragenyx Pharmaceutical has higher upside potential than Ligand Pharmaceuticals, analysts believe Ultragenyx Pharmaceutical is more attractive than Ligand Pharmaceuticals.

Ligand Pharmaceuticals has a beta of 0.874, which suggesting that the stock is 12.628% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.261, suggesting its less volatile than the S&P 500 by 73.884%.

Ligand Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ligand Pharmaceuticals pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Ligand Pharmaceuticals quarterly revenues are $45.3M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Ligand Pharmaceuticals's net income of -$42.5M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Ligand Pharmaceuticals's price-to-earnings ratio is 46.13x while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ligand Pharmaceuticals is 13.05x versus 4.63x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.